An outbreak of “Pneumonia of Unknown Etiology” occurred in Wuhan, China, in late December 2019. Later, the agent factor was identified and coined as SARS-CoV-2, and the disease was named coronavirus disease 2019 (COVID-19). In a shorter period, this newly emergent infection brought the world to a standstill. On 11 March 2020, the WHO declared COVID-19 as a pandemic. Researchers across the globe have joined their hands to investigate SARS-CoV-2 in terms of pathogenicity, transmissibility, and deduce therapeutics to subjugate this infection. The researchers and scholars practicing different arts of medicine are on an extensive quest to come up with safer ways to curb the pathological implications of this viral infection. A huge number of clinical trials are underway from the branch of allopathy and naturopathy. Besides, a paradigm shift on cellular therapy and nano-medicine protocols has to be optimized for better clinical and functional outcomes of COVID-19-affected individuals. This article unveils a comprehensive review of the pathogenesis mode of spread, and various treatment modalities to combat COVID-19 disease.

Introduction: Recently the idea of "Orthobiologics" leads to development of less invasive procedures and accelerated treatments which enhances functional recovery of musculoskeletal disorders. The desired therapeutic effect of autologous platelet rich plasma is facilitated by the ability of IL-1-Ra to limit the destructive inflammatory intra-articular (IA) actions of IL-1β. Objectives: To evaluate the efficacy and functional outcome of autologous PRP injection and homologous platelet lysate to reduce pain, improve joint function and enhance quality of life in patients with early knee osteoarthritis and to investigate the advantages and disadvantages of PRP and homologous platelet lysate. Material and Methods: A total of 121 cases of early osteoarthritis were equally divided into PRP and homologous platelet lysate group. Each patient in both groups has been given ultrasound guided PRP and homologous platelet lysate on day 0, at the end of 4 weeks and 8 weeks and all the patients were followed for up to one year. Treatment outcome measures were assessed at each visit using VAS and WOMAC scores. Results: A statistically significant improvement is observed with VAS and WOMAC score in knee osteoarthritis patients over 12 months with greater advantages over homologous platelet lysate. The overall reduction of pain and enhanced joint function was observed within 1 week, 3 months and 12 months after the initial injection. Conclusion:Homologous platelet lysate has the potential to offer chondroprotective and molecular approach in treating pain and functionality in patients with mild and moderate knee osteoarthritis with greater advantages over autologous platelet rich plasma.

Recent advances in molecular and nanobiology have led to the identification of specific cytokines that mediate cellular activities which becomes a powerful tool in management of orthopaedic disorders.Platelet rich plasma is a potential "Orthobiologic" agent for treating inflammatory and degenerative musculoskeletal disorders. Platelet rich plasma therapy aimed in rejuvenating the degenerating tissues by neoangiogensis and neoinnervation thus by increasing the texture and biology of the diseased tissues. This article outlines the guidelines for the usage, precautions, pre and post injection events of autologous platelet rich plasma therapy in musculoskeletal disorders.

Low back ache constitute a group of symptoms with no clear etiopathogenesis and pose a major difficulty for a health care professional to diagnose and treat the disease per se. Low back ache has become permanent disability for certain individuals and interferes with normal functioning of day-to-day life activities. This study was undertaken to establish the correlation and functional outcome between combination of Vitamin D & magnesium supplementation and Vitamin D supplementation for patients with non-specific low back ache. An observational comparative study was performed with 117 patients of non-specific low back ache from June 2019 to May 2020. Out of 117 patients, a total of 60 patients (Group A) were treated with a combination of Vitamin D supplementation along with magnesium tablets for 3 consecutive months and remaining 57 patients (Group B) were treated with Vitamin D supplementation for 3 consecutive months. Both the groups were followed up for 6 months for pain relief assessed by VAS score and functional improvement in quality of life assessed by Oswestry Low Back Pain Disability Questionnaire. A significant difference was noted in the Group A compared to Group B which demonstrates an additive effect on the combination used in them. When analysing the change in parameters compared to the pre-interventions state both the groups showed significant improvements. However, upon analysis of the correlation between the parameters with regard to the change among the groups, we noted that Group A showed significant correlation with respect to the Calcium and Vit-D level improvement out of the intervention upon the observed results. Treatment of non-specific low back ache with vitamin-D and magnesium shows synergistic effects with significant improvement in the functional outcomes and the pre-intervention metabolic parameters.

No abstract